国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

已收盘 04-14 16:08:20

20.380

+0.060

+0.30%

最高21.040	最低20.140	成交量449.74万
今开21.040	昨收20.320	日振幅4.43%
总市值636.06亿	流通市值273.46亿	总股本31.21亿
成交额9,139万	换手率0.34%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":20.38,"timestamp":1776154100004,"preClose":20.32,"halted":0,"volume":4497383,"delay":0,"changeRate":0.002952755905511748,"floatShares":1341810740,"shares":3121000000,"eps":2.6339861043660804,"marketStatus":"已收盘","change":0.06,"latestTime":"04-14 16:08:20","open":21.04,"high":21.04,"low":20.14,"amount":91394974,"amplitude":0.044291,"askPrice":20.38,"askSize":38400,"bidPrice":20.34,"bidSize":8800,"shortable":3,"etf":0,"ttmEps":2.6339861043660804,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776216600000},"marketStatusCode":5,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":20.32,"dividendRate":0.03629,"openAndCloseTimeList":[[1776130200000,1776139200000],[1776142800000,1776153600000]],"volumeRatio":0.903161,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.2939,"impliedVolPercentile":0.6434},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"1184054216","title":"国药控股3月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1184054216","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184054216?lang=zh_cn&edition=full","pubTime":"2026-04-09 06:21","pubTimestamp":1775686888,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司于2026年4月9日披露2026年3月股份变动月报。根据公告，截至2026年3月31日，公司注册股本数额及已发行股份总数均保持稳定，未有新增发行、购回或注销活动。注册股本方面，公司H股注册股本为1,341,810,740股，内资股注册股本为1,778,845,451股，合计3,120,656,191股。报告期内，H股与内资股的数量均未发生变化。公司在报告期内未披露任何股份期权或股权激励计划的变动，也无购回或注销股份的记录。公告由公司秘书吴壹建签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624525647","title":"国药控股等在北京成立供应链公司 注册资本28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624525647","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624525647?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:01","pubTimestamp":1775091660,"startTime":"0","endTime":"0","summary":"人民财讯4月2日电，企查查APP显示，近日，国药（北京）供应链有限公司成立，注册资本28亿元，经营范围包含：供应链管理服务；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广。企查查股权穿透显示，该公司由国药控股等共同持股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023692887288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1115378108.SGD","BK1500","01099","BK1197","BK1515","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125259337","title":"国药控股2025年度营收73.42亿元，经调整净利润10.96亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125259337","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125259337?lang=zh_cn&edition=full","pubTime":"2026-04-01 22:15","pubTimestamp":1775052948,"startTime":"0","endTime":"0","summary":"本季度信息\n国药控股（股票代码：01099）公布的公告数据显示，截至2025年12月31日止年度，公司实现营收73.42亿元，同比下降1.29%。经调整净利润为10.96亿元，同比上升88.53%。经营活动产生的现金流量净额录得16.39亿元，同比减少49.91%。公告指出，本期净利润显著增长主要因为商誉及无形资产计提减值准备同比减少6.86亿元，同时门店调整带来的人工及租金等刚性费用成本下降所致。\n业务分项\n高管解读","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0634319403.HKD","BK1515","HK0000165453.HKD","LU2488822045.USD","09688","BK1161","IE00B543WZ88.USD","BK1583","BK1147","BK1100","03933","LU0405327494.USD","IE00BPRC5H50.USD","LU1969619763.USD","BK0028","02268","LU2399975544.HKD","LU2495084118.USD","01530","LU0348783233.USD","LU0348766576.USD","LU1328615791.USD","01789","06821","LU1255011170.USD","600030","LU0405327148.USD","LU1719994722.HKD","LU1770034418.SGD","06160","LU2148510915.USD","LU0307460666.USD","LU0348735423.USD","BK1588","BK1564","02228","BK1617","02196","01099","BK1191","LU1115378108.SGD","LU1303224171.USD","BK1593","BK0276","LU1997245177.USD","06030","BK0012","LU2476274308.USD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623366194","title":"国药控股获Lazard Asset Management LLC增持约209.6万股 每股作价约19.59港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623366194","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623366194?lang=zh_cn&edition=full","pubTime":"2026-03-30 07:38","pubTimestamp":1774827480,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　据香港联交所最新数据显示，3月24日，Lazard Asset Management LLC增持国药控股（01099）209.6025万股，每股作价19.5897港元，总金额约为4106.05万港元。增持后最新持股数目约为1.76亿股，持股比例为13.13%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-30/doc-inhsthzk6657983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1115378108.SGD","BK1515","BK1197","BK1500","01099","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622806486","title":"国药控股（雄安）有限公司揭牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2622806486","media":"滚动播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622806486?lang=zh_cn&edition=full","pubTime":"2026-03-28 06:47","pubTimestamp":1774651620,"startTime":"0","endTime":"0","summary":"转自：河北日报国药控股（雄安）有限公司揭牌     本报讯3月27日，国药控股（雄安）有限公司揭牌仪式暨健康中国引领下医药行业发展大会在雄安新区举行。国药控股（雄安）有限公司作为集团核心医药商业平台，具备覆盖全国的医药供应链网络和国际领先的物流能力。在雄安自贸试验区管委会的靠前服务、精准对接下，国药控股（雄安）有限公司已于1月19日在雄安自贸大厦完成注册。中国医药集团有限公司负责人说。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-28/doc-inhsnuva4753815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1197","LU1115378108.SGD","BK1515","01099","BK1500","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622825483","title":"Lazard Asset Management LLC增持国药控股(01099)约209.6万股 每股作价约19.59港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622825483","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622825483?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:14","pubTimestamp":1774610092,"startTime":"0","endTime":"0","summary":"3月24日，Lazard Asset Management LLC增持国药控股(01099)209.6025万股，每股作价19.5897港元，总金额约为4106.05万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260327/20260327191409_44237.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260327/20260327191409_44237.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0640798160.USD","BK1197","BK1500","LU1115378108.SGD","BK1515","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622047303","title":"【券商聚焦】华泰研究维持国药控股(01099)“买入”评级 指零售板块领衔增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622047303","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622047303?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:31","pubTimestamp":1774420277,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰研究发布研报指，国药控股 2025年收入为5752亿元人民币，同比下降1.6%，归母净利润为71.6亿元，同比增长1.5%，符合市场预期。展望2026年，随着药品及器械分销业务结构持续优化带动收入企稳，零售板块批零协同深化经营改善，预计公司净利润将继续保持正增长。零售业务2025年收入为384亿元，同比增长6.67%，成为集团领衔增长的板块，经营溢利率提升0.66个百分点至1.56%，主要得益于整体降本增效的费用管控及国大药房显著减亏。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621550420","title":"瑞银：微升国药控股(01099)目标价至25.7港元 预料今年收入增长胜同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2621550420","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621550420?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:30","pubTimestamp":1774333840,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，国药控股(01099)2025年总收入5,751亿元人民币(下同)，同比跌1.6%；股东应占净利润71.6亿元，同比升1.5%，均大致符预期。行业政策逆风持续对分销收入构成压力，但该行认为公司的成本控制和业务优化降低了营运费用率。该行上调2026至2028年每股盈利预测1%至2%，维持“买入”评级，目标价由24.2港元上调至25.7港元。该行预期，公司今年收入增长将快于行业，主要受惠于市场份额提升、创新药分销业务及零售业务，净利润率有望轻微扩张。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621037229","title":"港股异动 | 国药控股(01099)跌近5% 去年纯利同比增长1.5% 花旗微降公司目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2621037229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621037229?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:49","pubTimestamp":1774324198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国药控股跌近5%，截至发稿，跌4.8%，报19.44港元，成交额5621.42万港元。消息面上，国药控股发布2025年度业绩，该集团取得收入人民币5751.68亿元，同比减少1.6%；母公司持有者应占溢利71.55亿元，同比增加1.5%；每股盈利2.29元，拟派发末期股息每股0.69元。花旗发布研报称，国药控股管理层在业绩会议上预期，今年药品分销业务销售额同比持平，医疗器械分销及零售业务则预期进一步复苏，录得正增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162249749","title":"异动解读 | 花旗下调目标价及业绩指引偏谨慎，国药控股盘中大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162249749","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162249749?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:36","pubTimestamp":1774319797,"startTime":"0","endTime":"0","summary":"国药控股今日盘中大跌5.04%，股价创下近期新低，引发市场关注。消息面上，花旗发布报告，将国药控股的目标价从23港元下调至22.8港元。同时，在公司业绩发布后的会议上，管理层对2026年的业务展望给出了指引，其中药品分销业务的销售额预计将同比持平，而器械分销和零售业务则预计将进一步复苏，实现同比正增长。分析认为，花旗下调目标价以及管理层对核心药品分销业务增长持平的预期，可能是导致投资者信心受挫、股价在交易时段内承压下跌的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","BK1207","LU1770034418.SGD","LU0348735423.USD","LU0417516902.SGD","LU0634319403.HKD","01530","06160","BK1583","LU2328871848.SGD","02228","BK1585","BK1191","01789","BK1161","BK1588","CXO","09926","IE00B543WZ88.USD","02367","LU0417516738.SGD","LU1303224171.USD","02196","LU2399975544.HKD","LU2476274308.USD","03329","BK1617","LU0348784397.USD","02268","BK1574","IE00BPRC5H50.USD","09688","06821","03933","LU1115378108.SGD","LU2488822045.USD","LU0348767384.USD","01099","LU0540923850.HKD","LU1794554557.SGD","LU0307460666.USD","BK1141","BK1197","BK1593","LU0348827113.USD","LU0417516571.SGD","BK1500","LU0348766576.USD","LU1719994722.HKD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621554742","title":"国药控股(01099)发布年度业绩，归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621554742","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621554742?lang=zh_cn&edition=full","pubTime":"2026-03-23 07:17","pubTimestamp":1774221459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股 发布截至2025年12月31日止年度业绩，该集团取得收入人民币5751.68亿元，同比减少1.6%;母公司持有者应占溢利71.55亿元，同比增加1.5%;每股盈利2.29元，拟派发末期股息每股0.69元。报告期内，经营性现金流实现净流入为141.38亿元，较上年同期多流入25.92亿元，现金流管理成效突出;应收账款增幅显著收窄，应收账款专项治理显效;资产负债率同比下降2.12个百分点。报告期内，三大主营业务板块延续差异化发展态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121922826","title":"国药控股将于2026年8月18日派发末期股息每股0.69元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121922826","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121922826?lang=zh_cn&edition=full","pubTime":"2026-03-23 06:22","pubTimestamp":1774218127,"startTime":"0","endTime":"0","summary":"国药控股(01099)\n2026年3月20日，公司公告拟派发截至2025年12月31日止年度的末期股息，每股人民币0.69元，待2026年6月18日股东大会审议通过后正式派发。公司预设以港币进行派息，具体金额及汇率尚未公布。\n根据公告，除净日定于2026年6月23日，股东如欲享有股息派发，须在2026年6月24日16:30前递交过户文件。股份过户登记将于2026年6月25日至6月30日暂停办理，2026年6月30日为记录日期。股息派发日为2026年8月18日。\n公告同时披露了适用于非居民企业、非个人民事主体及港股通等不同类型投资者的代扣所得税税率安排，最高预扣税率为20%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187221455","title":"国药控股2025年度营收524.68亿元，净利润19.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187221455","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187221455?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:43","pubTimestamp":1773927789,"startTime":"0","endTime":"0","summary":"本季度信息\n国药控股（股票代码：01099）公布2025年度财报。财报显示，公司在报告期内实现营收52,468,280,576.72元，同比增长3.70%。同期，公司扣除非经常性损益后的净利润为1,970,533,716.86元，同比下降1.28%。财报同时显示，经营活动产生的现金流量净额达到2,005,517,512.06元，同比上升20.88%。整体来看，公司业务规模稳步提升，盈利能力保持相对稳定。\n业务分项\n高管解读","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225019","title":"国药控股(01099)：国药器械年度营业利润12.49亿元 同比增加2.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225019","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620225019?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:36","pubTimestamp":1773927365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布公告，本公司附属公司中国医疗器械有限公司(国药器械)截至2025年12月31日止年度取得营业收入748.93亿元，同比减少2.35%;营业利润12.49亿元，同比增加2.38%;归属于母公司所有者的综合收益5.07亿元，同比增加25.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","BK1500","LU0640798160.USD","BK1515","LU1115378108.SGD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182437015","title":"国药控股(01099)2025年度营收748.93亿元，经调整净利润5.07亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182437015","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182437015?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:31","pubTimestamp":1773927072,"startTime":"0","endTime":"0","summary":"本年度信息\n国药控股(01099)发布的最新财报显示，2025年度公司营收为748.93亿元，同比下降2.35%。同期，经调整后净利润为5.07亿元，同比增长25.64%。经营利润为12.49亿元，经营利润率约为1.67%，相比上年同期略有提升。\n经营活动产生的现金流量净额为7.39亿元，去年同期为-13.56亿元。本期末，公司总资产达573.02亿元，同比下降7.07%；归属于母公司所有者权益合计为83.00亿元，同比增长5.27%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191540618","title":"国药控股(01099)2025年度营收734.16亿元，经调整净利润109.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191540618","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191540618?lang=zh_cn&edition=full","pubTime":"2026-03-18 06:16","pubTimestamp":1773785800,"startTime":"0","endTime":"0","summary":"根据公告披露，国药控股旗下国药集团一致药业股份有限公司在截至2025年12月31日止年度实现营业收入734.16亿元，同比下降1.29%。经营利润达到15.13亿元，同比增幅163.80%。经调整后归属于上市公司股东的净利润为109.57亿元，同比上涨88.53%。公告指出，报告期内利润增长主要由于商誉及无形资产减值计提同比减少，以及人力与租金等刚性费用随门店调整而下降所致。公告提及，2026年是“十五五”规划的开局之年，亦是国药一致深化转型、迈向高质量发展的关键时期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619166690","title":"国药控股获摩根大通增持74.98万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619166690","media":"和讯网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619166690?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:05","pubTimestamp":1773324303,"startTime":"0","endTime":"0","summary":"格隆汇3月12日丨根据联交所最新权益披露资料显示，2026年3月9日，国药控股(01099.HK)获JPMorgan Chase & Co.以每股均价20.4501港元增持好仓74.98万股，涉资约1533.32万港元。增持后，JPMorgan Chase & Co.最新持好仓数目为6767.56万股，持好仓比例由4.98%上升至5.04%。本文来自和讯财经，更多精彩资讯请下载“和讯财经”APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312220754954a8972&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312220754954a8972&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099","BK1515","BK1500","BK1197","LU1115378108.SGD","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619669581","title":"国药控股03月12日获主力加仓1372.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619669581","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619669581?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:15","pubTimestamp":1773303328,"startTime":"0","endTime":"0","summary":"03月12日, 国药控股股价涨1.25%，报收21.06元，成交金额1.5亿元，换手率0.54%，振幅2.88%，量比1.22。国药控股今日主力资金净流入1372.6万元，上一交易日主力净流入2310.1万元。近一年数据显示，该股主力连续10日净流入后，次日上涨概率为50.00%，平均涨幅为0.98%。该股近5个交易日下跌0.87%，主力资金累计净流入6325.0万元；近20日主力资金累计净流入2.0亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161645a6ba4121&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161645a6ba4121&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1500","LU0640798160.USD","01099","BK1197","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":-0.0287},{"period":"1month","weight":-0.0388},{"period":"3month","weight":-0.0155},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.1859},{"period":"ytd","weight":0.0453}],"compareEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004643},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029413},{"month":3,"riseRate":0.470588,"avgChangeRate":0.007007},{"month":4,"riseRate":0.470588,"avgChangeRate":0.021873},{"month":5,"riseRate":0.625,"avgChangeRate":-0.004548},{"month":6,"riseRate":0.4375,"avgChangeRate":-0.005852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.015111},{"month":8,"riseRate":0.4375,"avgChangeRate":0.012101},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.011177},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042295},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.007287},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004122}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}